Daniel Faga is the President and CEO of AnaptysBio, Inc., a biotech company known for developing innovative treatments. He has a solid educational background with a B.S. in Engineering and an M.B.A. in Healthcare Management. Faga stepped into the CEO role in 2023 after serving as Interim President since March 2022. His experience spans over 20 years in the life sciences sector, where he held positions such as Chief Operating Officer at Mirati Therapeutics and Chief Business Officer at Spark Therapeutics. Under his leadership, AnaptysBio focuses on creating groundbreaking therapies, particularly for inflammation and immune-related conditions. Notably, his compensation package includes a $1.5 million transition bonus, which reflects a strong financial incentive tied to performance metrics.

Number of Employees

117

2023 2022

Year

2023

Total Compensation

$992.94K

Salary

$640.61K

Board Justification

The compensation program is designed to reward executive officers at a level consistent with overall strategic and financial performance, with a significant portion tied to performance metrics and stockholder returns.

Bonus

$352.33K

Board Justification

The annual target cash bonus opportunity of up to 55% of base salary, earned based on the achievement of specified performance goals for 2023.

Other

$0.00

Board Justification

No additional compensation was reported outside of salary and bonus for 2023.

Restricted Stock

$0.00(0 RSU)

Board Justification

No stock was vested in 2023 as the focus is on cash compensation and performance-based bonuses.

Performance Metrics

Performance metrics for the 2023 cash bonus plan included corporate goals related to clinical trials and financial management.

SEC Filing

From April 24, 2024

View SEC Filing

Daniel Faga

Ex-CEO of AnaptysBio, Inc.

Education

MBA from Harvard Business School

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Born

November 20, 1977 - 47 years ago

Is Founder?

Tenure

1 year 2 months (Apr 2022 - Jun 2023)

Previous Experience

Chief Operating Officer at Mirati Therapeutics

Predecessor

Hamza Suria

September 2011 - March 2022

Successor

John Doe

July 2023 - Present